Xin Lang Cai Jing·2025-10-30 04:14Core Insights - Junshi Bioscience reported a Q3 revenue of 637 million yuan, representing a year-on-year growth of 31.4%, with a total revenue of 1.806 billion yuan for the first three quarters, marking a 42.06% increase [1][2] Revenue Growth - The revenue growth in the first three quarters was primarily driven by the increase in sales of commercialized drugs, particularly the core product PD-1 inhibitor Toripalimab (brand name: Tuoyi), which achieved sales of approximately 1.495 billion yuan in the domestic market, reflecting a year-on-year growth of about 40% [2] Financial Management - Junshi Bioscience has implemented a "quality improvement and efficiency enhancement" action plan, focusing on cost control and resource allocation, resulting in a significant reduction in losses compared to the same period last year [2] Cash Position - As of the end of the reporting period, the total balance of cash and trading financial assets for Junshi Bioscience was 3.27 billion yuan [2] Product Development - The application for a new indication of Tuoyi for first-line treatment of HER2-expressing urothelial carcinoma has been accepted by the NMPA in China. Currently, Tuoyi has been approved for 12 indications in mainland China, with 10 of these included in the national medical insurance catalog [2] International Expansion - Toripalimab has been approved for marketing in over 40 countries and regions, including mainland China, Hong Kong, the United States, the European Union, India, the United Kingdom, Jordan, Australia, Singapore, the UAE, Kuwait, Pakistan, and Canada, and is undergoing market review in several other countries [2] Pipeline Progress - The clinical trial application for JS207 (PD-1/VEGF bispecific antibody) for neoadjuvant treatment in non-small cell lung cancer patients has been approved by the FDA in the United States. Additionally, the Phase III clinical study of JS005 (anti-IL-17A monoclonal antibody) for moderate to severe plaque psoriasis has met its primary endpoint, and the clinical trial application for JT118 injection (monkeypox virus recombinant protein vaccine) has been approved by the NMPA in China [3]